Colombia’s New Pricing Decree Could Impact Drug Registration, Warns Industry Group
Executive Summary
The pharmaceutical industry in Colombia is concerned that a new pricing decree could impact the regulatory process for new drugs.
You may also be interested in...
Colombian Pharma Industry Raises Concerns Over Pricing Proposals
A draft circular on pricing has raised the spectre of price controls being applied with little warning for companies, the Colombian research-based pharmaceutical industry has warned.
USTR Takes Aim At Colombia Over Drug Pricing Policy
Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.
USTR Takes Aim At Colombia Over Drug Pricing Policy
Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.